Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology-Reference-Cited by-同舟云学术

Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology

Published:2020-04-23 Issue:5 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Simon Julia¹²,Liu Zhiwei³^ORCID,Brenner Nicole¹,Yu Kelly J.³,Hsu Wan-Lun⁴⁵,Wang Cheng-Ping⁶,Chien Yin-Chu⁴⁷,Coghill Anna E.³⁸,Chen Chien-Jen⁴⁵,Butt Julia¹,Proietti Carla⁹,Doolan Denise L.⁹,Hildesheim Allan³,Waterboer Tim¹

Affiliation:

1. Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany

2. Faculty of Biosciences, Heidelberg University, Heidelberg, Germany

3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA

4. Genomics Research Center, Academia Sinica, Taipei, Taiwan

5. Graduate Institute of Epidemiology and Prevention Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

6. Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan

7. National Institute of Cancer Research, National Health Research Institute, Miaoli, Taiwan

8. Cancer Epidemiology Program, Division of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA

9. Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia

Abstract

Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvigorated by the implementation of novel Epstein-Barr virus (EBV)-specific IgA and IgG antibodies from a proteome array. Although proteome arrays are well suited for comprehensive antigen selection, they are not applicable for large-scale studies. We adapted a 13-marker EBV antigen signature for NPC risk identified by proteome arrays to multiplex serology to establish an assay for large-scale studies. Taiwanese NPC cases ( n = 175) and matched controls ( n = 175) were used for assay validation.

Funder

NCI Intramural Funding

DKFZ Intramural Funding

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00077-20

Reference30 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma

3. American Cancer Society. 2017. Cancer Facts & Figures 2017. American Cancer Society Atlanta GA. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html.

4. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience

5. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A proteome‐wide analysis unveils a core Epstein–Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations;International Journal of Cancer;2024-07-12

2. Multiplex assays reveal anti‐EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma;International Journal of Cancer;2024-06-18

3. Prospective evaluation of the relevance of Epstein–Barr virus antibodies for early detection of nasopharyngeal carcinoma in Chinese adults;International Journal of Epidemiology;2024-06-12

4. Kinetics of EBV antibody‐based NPC risk scores in Taiwan NPC multiplex families;International Journal of Cancer;2024-06

5. Could MMP3 and MMP9 Serve as Biomarkers in EBV-Related Oropharyngeal Cancer;International Journal of Molecular Sciences;2024-02-22